Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality.

ABSTRACT:

Importance

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have gained use primarily due to their weight-reduction effects, although a regulatory review was undertaken for potential suicidality concern.

Objectives

To evaluate potential signals for suicidal and self-injurious adverse drug reactions (ADRs) associated with the GLP-1 RAs semaglutide and liraglutide.

Design, setting, and participants

Disproportionality analysis through the case-control design using the World Health Organization (WHO) global database of suspected ADRs. Participants were clinical patients worldwide experiencing an ADR suspectedly attributable to semaglutide or liraglutide in the database from inception to August 30, 2023. Data were analyzed from September to December 2023.

Exposure<

SUBMITTER: Schoretsanitis G 

PROVIDER: S-EPMC11337067 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature